pigmented purpuric eruption
MONDO:0008248
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Pigmented purpuric dermatosis
Pigmented purpuric dermatosis refers to one of the three major classes of skin conditions characterized by purpuric skin eruptions. Pigmented purpuric dermatosis are distinguished from other purpura by size (0.3–1 cm) and are most often seen in the lower extremities. Pigmentary purpuric eruptions may present with one of several clinical patterns. There may be overlapping characteristics among pigmented purpuric dermatosis and between their signs and those of other purpuric eruptions. Examples of the pigmented purpuric dermatosis group include: Schamberg's disease Majocchi's disease (Purpura annularis telangiectodes) Gougerot-Blum syndrome (Pigmented purpuric lichenoid dermatitis) Ducas and Kapetanakis pigmented purpura Lichen aureus Although vascular damage may be present, it is insufficient for these conditions to be considered forms of vasculitis. A few very small non-blinded studies of treatment with narrow-band ultraviolet light have been reported as promising.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.